Search
Epinephrine
go.drugbank.com/drugs/DB00668ApprovedInvestigationalVet approvedMany new products/biosimilars and dosage routes have been approved under various names over the last several decades [L4355], [L4356], [L4358].
International brands: Epi EZ Pen JRMixtures: Marcaine E, Marcaine EAlbutrepenonacog alfa
go.drugbank.com/drugs/DB13884ApprovedIt was also approved by FDA and EMA in 2016. It is currently marketed in the forms of 250, 500, 1000 and 2000 IU/vial.[L2305]
Products: IDELVION 250 IU powder and solvent for solution for injection, IDELVION 500 IU powder and solvent for solution for injectionDordaviprone
go.drugbank.com/drugs/DB14844ApprovedInvestigationalOn August 6, 2025, dordaviprone was granted accelerated approval by the FDA.[L53838] It is used to treat patients with diffuse midline glioma harboring an H3 K27M mutation. … activation of mitochondrial caseinolytic protease P (ClpP), antagonism of the dopamine D2 receptor,[L53833] activation of Activating Transcription Factor 4 (ATF4), and induction of endoplasmic reticulum (ER
Synonyms: 7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo(1,2-A)pyrido(3,4-E)pyrimidin-5(4H)-one, 2,4,6,7,8,9-Hexahydro-4-((2-methylphenyl)methyl)-7-phenylmethyl)imidazo)(1,2-a)pyrido(3,4-e)pyrimidin-5(1H)-oneSalmeterol
go.drugbank.com/drugs/DB00938ApprovedInvestigational[A183737] Salmeterol was granted FDA approval on 4 February 1994.[L11542]
Mixtures: SALFLUTIN 50/100UG 60 ED, SALFLUTIN 50/250UG 60 EDOxymetazoline
go.drugbank.com/drugs/DB00935ApprovedInvestigational[L15062] As an effective decongestant, oxymetazoline is available in over-the-counter intranasal sprays used to relieve nasal and sinus congestion caused by a wide variety of conditions, such as common … [L15057] In July 2020, the FDA approved the use of an ophthalmic formulation of oxymetazoline (Upneeq) in adults with acquired blepharoptosis, or ptosis, making it the first FDA-approved medical treatment
Caplacizumab
go.drugbank.com/drugs/DB06081ApprovedInvestigationalCaplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression … [A174634]In December 2025, the FDA expanded this indication to include pediatric patients aged 12 years and older with aTTP, in the same combination regimen.[L54958,L54963]
Trastuzumab
go.drugbank.com/drugs/DB00072ApprovedInvestigational[L14015] It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic breast cancer, where there is a proven amplification of the HER-2 oncogene or over-expression of the HER … Kanjinti (trastuzumab-anns)[L14135] and Hercessi[L52840] are other biosimilars approved by the FDA. In Canada, biosimilars ONTRUZANT[[L40303, L40308] and Adheroza[L52835] are approved.
Categories: HER2/Neu/cerbB2 AntagonistsPrednisolone acetate
go.drugbank.com/drugs/DB15566ApprovedInvestigationalVet approved[L9449] Prednisolone acetate was granted FDA approval in 1955.[L9449]
Levonordefrin
go.drugbank.com/drugs/DB06707ApprovedInvestigationalLevonordefrin acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry.
Neratinib
go.drugbank.com/drugs/DB11828ApprovedInvestigationalNeratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib i...